Recent advances in biomarker discovery have revolutionized the field of lymphoma treatment. Among this progress, liquid biopsy has emerged as a promising approach for detecting minimal residual disease (MRD). Unlike traditional biopsies that require tissue sampling, liquid biopsies analyze circulating tumor cells (CTCs) and detached DNA in the bloo

Minimal residual disease (MRD) identification is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-fr

Minimal residual disease (MRD) detection is crucial in lymphoma management as it predicts relapse risk and guides therapeutic decisions. Traditional MRD methods often involve invasive biopsies, leading to patient discomfort and potential complications. Liquid biopsy, a non-invasive technique analyzing circulating tumor cells (CTCs) and cell-free DN

Liquid biopsy has emerged as a promising method for detecting minimal residual disease (MRD) in lymphoma. Unlike traditional tissue biopsies, which are invasive, liquid biopsy analyzes cell-free DNA present in bodily fluids such as plasma. This gentle procedure allows for frequent evaluation of MRD levels, offering valuable insights to guide manage